Krishnan Patel, MD, MHS
@krishnan_patel
Academic Radiation Oncologist. All views are my own and not reflective of my employer.
You might like
Check out our recent review on enhanced systemic therapy for localized prostate cancer now freely available: authors.elsevier.com/a/1lFrI3lXQoc1… A big thanks to our team (@melissaabel20, @SBasourakos, @DeborahCitrin) and Ravi (@Dr_RaviMadan) for his leadership on this one!
2025 summary of our original research articles in #prostatecancer 🟢🟢🟢🟢🔵🟠🟡🟡🟡⚪️⚪️⚪️⚪️🟣🟣🟣🟣🟣🟣🟣🟣 (published=🟢, accepted=🔵, revision=🟠, under review=🟡, draft=⚪️, data analysis=🟣) #CancerResearch #AI #Radiology #TeamScience #Teamwork #ArtificialIntelligence…
@PaulSargos ; @Achard_Verane ; @a_dalpra ; @abhiAsolanki ; @drjefstathiou ; @krishnan_patel ; @Dr_RaviMadan ; @DeborahCitrin 9/n
Does short-term ADT continue to show benefit after the negative results of NRG/RTOG 0815? @krishnan_patel, @DrSpratticus, @tranpt21, Daniel Krauss, Anthony D'Amico, and @DrPaulNguyen provide an up-to-date analysis suggesting continued benefit. tinyurl.com/redpatel
🎉 Excited to share our latest work: RadOncCalc – A Mobile-Friendly Tool to Enhance Radiation Oncology Practice 📱⚛️ How does RadOncCalc help radiation oncologists save time and enhance patient care? Let’s break it down in this Tweetorial! practicalradonc.org/article/S1879-… 🧵👇
🎉Excited to share our new publication "Evaluating deep learning and radiologist performance in volumetric prostate cancer analysis with biparametric MRI and histopathologically mapped slides" 👏Huge congratulations to @eniscy for leading this big project with our amazing team…
Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncolo… pubmed.ncbi.nlm.nih.gov/39542826/ @krishnan_patel @NRGonc
In the most comprehensive head-to-head comparison of modern AI-based LLMs for application in oncology, a significant heterogeneity in model accuracy was observed, with GPT-4 showing performance competitive with a human benchmark. nejm.ai/4aJWOAY
New in #practicalRO: Target Volume Optimization for Localized Prostate Cancer. #radonc tinyurl.com/propatel
Phase I trial investigates salvage SBRT, revealing promising biochemical control but highlighting significant moderate-grade toxicities. While early results are encouraging, optimal dosing and broader application remain under study > bit.ly/3MhNV6I @krishnan_patel @NIH
Phase I trial investigates salvage SBRT, revealing promising biochemical control but highlighting significant moderate-grade toxicities. While early results are encouraging, optimal dosing and broader application remain under study > bit.ly/3MhNV6I @krishnan_patel @NIH
United States Trends
- 1. Marshawn Kneeland 11.1K posts
- 2. Nancy Pelosi 15.9K posts
- 3. #MichaelMovie 22.7K posts
- 4. ESPN Bet 1,933 posts
- 5. Gremlins 3 2,016 posts
- 6. #NO1ShinesLikeHongjoong 16.9K posts
- 7. Good Thursday 34K posts
- 8. Jaafar 6,645 posts
- 9. Madam Speaker N/A
- 10. #영원한_넘버원캡틴쭝_생일 16.7K posts
- 11. #thursdayvibes 2,693 posts
- 12. Happy Friday Eve N/A
- 13. Joe Dante N/A
- 14. Mega Chimecho 3,219 posts
- 15. Penn 9,013 posts
- 16. #BrightStar_THE8Day 26.1K posts
- 17. Baxcalibur 2,711 posts
- 18. Chris Columbus 1,858 posts
- 19. Korrina 2,949 posts
- 20. Diantha N/A
You might like
-
Coach Benders
@CoachBenders910 -
Medical.watch
@MedicalwatchHQ -
Aditya Raghunandan, MD, RMSK
@RaghunandanMD -
Matt Fleming
@mattmfleming -
Alan Baik
@baik_alan -
Adam J. Schoenfeld
@AdamJSchoenfeld -
Pleasant Local Athletics
@pls_spartans -
J Dawn
@JDawnOfficial -
Danny Vélez
@dannyvelzmusic -
Faraz
@FarazAhmadMD -
Nicholas I Simon, MD MSc
@NicholasISimon
Something went wrong.
Something went wrong.